| Home > People > Keith Williams, Special Advisor |
 |
Keith Williams, AM, FTSE, PhD, Senior Advisor – Biotech, IP Strategy & Technology Commercialization
Keith Williams is founder of Proteome Systems (PXL), a biotechnology company headquartered in Sydney and listed on the ASX. He holds Adjunct Professorships at both The University of Sydney and Macquarie University.
He has been involved with development and commercialisation of a range of biotech products over the last 15 years, either through strategic advice or company building. In the past decade his major emphasis has been on commercialising the field of proteomics, which his group named. Initially this involved building (in 1996) the world's first major national proteomics facility (APAF) in Sydney , but commercialisation was implemented through the formation of Proteome Systems Ltd in 1999. He left the University environment after a distinguished academic career, training 38 PhD students and publishing 295 papers in the fields of proteomics, cell, molecular and developmental biology. Professor Williams co-edited the first book about Proteomics, in 1997 “Proteome Research: New Frontiers in Functional Genomics” (Springer Verlag).
Keith Williams graduated in Agricultural Science from the University of Melbourne as a University Medallist. He completed his PhD in Biochemistry at the Australian National University in 1973, spent 2 years at the University of Oxford, UK, followed by 5 years at the Australian National University as a Research Fellow. From 1980-1983 he was a Nachwuchsgruppenleiter at the Max Planck Institute for Biochemistry in Munich , Germany . In 1984, he was appointed to a Professorship at Macquarie University in Sydney . In 1999, he founded (as Chief Executive Officer) along with key researchers in his team, Proteome Systems Ltd, which is located in the high technology Biohub at North Ryde in Sydney. He led Proteome Systems Initial Public Offering on the Australian Stock Exchange in 2004. He has been a frequent contributor to business forums and in 2004 was made a Member of the Order of Australia and a Fellow of the Australian Academy of Technological Sciences and Engineering. Currently he is exploring new biotech opportunities in the Asia/Pacific region.
|
|
Profiles 